Persistence with biologic therapies in the medicare coverage gap

American Journal of Managed Care

Volumn 17, Issue 11, 2011, Pages 753-759

  Tamariz, Leonardo ^a   Uribe, Claudia L ^b   Luo, Jiacong ^b   Hanna, John W ^b   Ball, Daniel E ^c   Krohn, Kelly ^c   Meadows, Eric S ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b HUMANA INC   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALENDRONIC ACID; BETA1A INTERFERON; ETANERCEPT; GENERIC DRUG; GLATIRAMER; PARATHYROID HORMONE[1-34];

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; DRUG COST; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; OSTEOPOROSIS; PATIENT CARE PLANNING; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT WITHDRAWAL;

AGED; ALENDRONATE; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL THERAPY; FEMALE; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; IMMUNOGLOBULIN G; INSURANCE COVERAGE; MALE; MEDICALLY UNINSURED; MEDICARE PART D; MIDDLE AGED; ODDS RATIO; PEPTIDES; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TERIPARATIDE; TIME FACTORS; UNITED STATES;

EID: 81455128911     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. US Congress. The Medicare Prescription Drug Improvement and Modernization Act of 2003. Public Law 108-173. Published 2003.
2. Cubanski J, Neuman P. Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage. Health Aff (Millwood). 2007;26(1):w1-w12.
3. Hoadley J, Thompson J, Hargrave E, Merrell K, Cubanski J, Neuman T. The Henry J. Kaiser Family Foundation. Medicare Part D 2008 Data Spotlight: Premiums. http://www.kff.org/medicare/upload/7706.pdf. Published November 2007. Accessed March 9, 2010.
4. Reed M, Brand R, Newhouse JP, Selby JV, Hsu J. Coping with prescription drug cost sharing: knowledge, adherence, and financial burden. Health Serv Res. 2008;43(2):785-797. (Pubitemid 351442595)
5. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354(22):2349-2359. (Pubitemid 43801280)
6. Zhang Y, Donohue JM, Newhouse JP, Lave JR. The effects of the coverage gap on drug spending: a closer look at Medicare Part D. Health Aff (Millwood). 2009;28(2):w317-w325.
7. Tseng CW, Brook RH, Keeler E, Steers WN, Mangione CM. Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292(8):952-960. (Pubitemid 39097205)
8. Neuman P, Strollo MK, Guterman S, et al. Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors. Health Aff (Millwood). 2007;26(5):w630-w643.
9. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45(2):197-203.
10. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care. 1995;33(8):783-795.
11. Piette JD, Heisler M, Wagner TH. Medication characteristics beyond cost alone influence decisions to underuse pharmacotherapy in response to financial pressures. J Clin Epidemiol. 2006;59(7):739-746. (Pubitemid 43825724)
12. Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med. 2007;22(6):864-871. (Pubitemid 46763978)
13. Hoadley J, Thompson J, Hargrave E, Merrell K, Cubanski J, Neuman T. The Henry J. Kaiser Family Foundation. Medicare Part D 2008 Data Spotlight: The Coverage Gap. http://www.kff.org/medicare/upload/7707. pdf. Published November 2007. Accessed September 30, 2009.
14. Conwell LJ, Esposito D, Garavaglia S, et al. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis [published online ahead of print May 26, 2011]. Am J Geriatr Pharmacother. In press.
15. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008:28(4):437-443. (Pubitemid 351466455)
16. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350. (Pubitemid 38656301)
17. Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006;25(5): 1319-1331. (Pubitemid 44497632)
18. Morris CA, Cheng H, Cagral D, Solomon DH. Predictors of screening and treatment of osteoporosis: a structured review of the literature. Endocrinologist. 2004;14(2):70-75. (Pubitemid 38420325)
19. Robb C, Hongbin C, Haley WE. Ageism in mental health and health care: a critical review. J Clin Geropsychol. 2002;8(1):1-12.
20. US Census Bureau. Current Population Survey, 2007 Annual Social and Economic (ASEC) Supplement. Washington, DC: US Census Bureau; March 2007. http://www.census.gov/apsd/techdoc/cps/cpsmar07. pdf. Accessed March 9, 2010.
21. Forteo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2009. http://pi.lilly.com/us/forteo-pi.pdf. Accessed March 9, 2010.
22. Tjia J, Briesacher BA, Soumerai SB, et al. Medicare beneficiaries and free prescription drug samples: a national survey. J Gen Intern Med. 2008;23(6):709-714.
23. Colby M, Esposito D, Goldfarb S, et al. Medication discontinuation and reinitiation among Part D beneficiaries taking costly medications. Am J Pharm Benefits. In press.
24. The Patient Protection and Affordable Care Act. http://www.gpo. gov/fdsys/pkg/PLAW-111publ148/pdf/PLAW-111publ148.pdf. Accessed July 26, 2011.